Sinocelltech: SCT640C injection has received approval for clinical trials
Sinocelltech announced that its holding subsidiary, Sinocelltech Engineering Co., Ltd., has received the drug clinical trial approval notice from the National Medical Products Administration for its self-developed product SCT640C injection, allowing the clinical trial for adult rheumatoid arthritis indications to proceed
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments